

8 September 2020

# ASX ANNOUNCEMENT

## ANTERIS GRANTED US PATENT ON STERILISATION METHOD

**Brisbane, Australia and Eagan, MN** - Anteris Technologies Ltd (ASX: AVR) (**Anteris** or the **Company**), a structural heart company advancing the DurAVR™ valve, a novel single-piece 3D aortic valve replacement solution, has been granted a patent in the United States for the sterilisation method employed in the manufacture of the Company's ADAPT® tissue.

The United States Patent Office granted the Company the patent on Sterilisation Method (U.S. Patent No. 10,758,642).

The patent describes sterilisation methods, invented by Professor Leon Neethling, that can be used with a collagen-based biomaterial. Professor Neethling is currently Vice-President Cardiovascular Technologies of Anteris Technologies Ltd and professor at School of Surgery at University of Western Australia.

Sterilisation is an important step in the Company's ADAPT® tissue technology process and key to the Company's manufacturing of ADAPT® tissue and its strategic supply partnerships.

The US patent generally covers a sterilised, cross-linked collagen-based biomaterial stored in a storage container with a storage solution of propylene glycol derived from a sterilisation solution comprising propylene oxide but no alcohol.

"Expanding our intellectual property portfolio is an area of continual focus. The ADAPT® tissue is a vital component of our DuraAVR™ single-piece 3D aortic valve, and therefore extending the IP portfolio is essential to our value creation strategy," Chief Executive Officer of Anteris Technologies, Mr Wayne Paterson, said.

**ENDS**

**Anteris Technologies Ltd**

**Registered Office:**

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

**Customer Service:**

T +61 1300 550 310 | F +61 1300 880 398 | E [info@anteristech.com](mailto:info@anteristech.com) | W [anteristech.com](http://anteristech.com)

Brisbane ▪ Minneapolis ▪ Geneva ▪ Malaga



## **About Anteris Technologies Ltd (ASX: AVR)**

Anteris Technologies Ltd is a structural heart company delivering clinically superior solutions that help create life-changing outcomes for patients. Its focus is on developing next generation technologies with world class partners.

Its ADAPT<sup>®</sup> tissue platform, a next generation technology with zero DNA and zero glutaraldehyde, is the only bio-scaffold to demonstrate zero calcification after 10 years of use in complex cardiac surgery. With these advantages, Anteris' best-in-class ADAPT<sup>®</sup> tissue combined with its valve design has the potential to solve the problems of durability and valve degradation associated with current aortic valve replacement options.

## **Authorisation and Additional information**

This announcement was authorised by Mr Wayne Paterson, Chief Executive Officer.

### **For more information:**

Ms Kyahn Williamson  
WE Communications  
E: [WE-AUAnterisTech@we-worldwide.com](mailto:WE-AUAnterisTech@we-worldwide.com)  
P: +61 401 018 828

[www.anteristech.com](http://www.anteristech.com)  
Twitter: @AnterisTech  
Facebook: [www.facebook.com/AnterisTech](http://www.facebook.com/AnterisTech)